Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Saad

Showing results (41-50 of 161) with videos related to

Pageof 17
Sort By:
The New England Journal of Medicine|November 1, 2016
Adaptive Randomization of Neratinib in Early Breast CancerMarc Buyse, Everardo D Saad, Tomasz Burzykowski
Cureus|November 8, 2019
Singultus as an Unusual Debut of Plasmodium vivax MalariaFrancisco Guadarrama-Conzuelo, Assad D Saad Manzanera
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2016
Neoadjuvant as Future for Drug Development in Breast Cancer--LetterMarc Buyse, Tomasz Burzykowski, Everardo D Saad
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|September 21, 2002
Critical noise levels for low-density parity check decodingJ Van Mourik, D Saad, Y Kabashima
Annals of Translational Medicine|July 20, 2018
The search for surrogate endpoints for immunotherapy trialsMarc Buyse, Tomasz Burzykowski, Everardo D Saad
The New England Journal of Medicine|June 2, 2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancerArtur Katz, Aknar Calabrich, Everardo D Saad
JAMA Oncology|November 29, 2016
Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open QuestionTomasz Burzykowski, Everardo D Saad, Marc Buyse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trialsEverardo D Saad, Artur Katz, Marc Buyse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Survival is not a good outcome for randomized trials with effective subsequent therapiesMarc Buyse, Daniel J Sargent, Everardo D Saad
Applied Optics|September 8, 2010
Four-quadrant optical matrix-vector multiplication machine as a neural-network processorS Abramson, D Saad, E Marom, et al.
Pageof 17

Showing results (41-50 of 161) with videos related to

Sort By:
Pageof 17
The New England Journal of Medicine|November 1, 2016
Adaptive Randomization of Neratinib in Early Breast CancerMarc Buyse, Everardo D Saad, Tomasz Burzykowski
Cureus|November 8, 2019
Singultus as an Unusual Debut of Plasmodium vivax MalariaFrancisco Guadarrama-Conzuelo, Assad D Saad Manzanera
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2016
Neoadjuvant as Future for Drug Development in Breast Cancer--LetterMarc Buyse, Tomasz Burzykowski, Everardo D Saad
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|September 21, 2002
Critical noise levels for low-density parity check decodingJ Van Mourik, D Saad, Y Kabashima
Annals of Translational Medicine|July 20, 2018
The search for surrogate endpoints for immunotherapy trialsMarc Buyse, Tomasz Burzykowski, Everardo D Saad
The New England Journal of Medicine|June 2, 2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancerArtur Katz, Aknar Calabrich, Everardo D Saad
JAMA Oncology|November 29, 2016
Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open QuestionTomasz Burzykowski, Everardo D Saad, Marc Buyse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trialsEverardo D Saad, Artur Katz, Marc Buyse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Survival is not a good outcome for randomized trials with effective subsequent therapiesMarc Buyse, Daniel J Sargent, Everardo D Saad
Applied Optics|September 8, 2010
Four-quadrant optical matrix-vector multiplication machine as a neural-network processorS Abramson, D Saad, E Marom, et al.
Pageof 17